<DOC>
	<DOCNO>NCT00451243</DOCNO>
	<brief_summary>Psoriasis multifactorial cutaneous disorder affect 100000 patient Taiwan . Psoriatic arthritis also present 20~30 percent . Many drug show aggravate psoriasis include drug use treatment psoriatic arthritis . On contrary , anti-psoriatic drug also know aggravate induce psoriatic arthritis . Psoriasis psoriatic arthritis believe share pathogenic lymphocyte , differential response drug intrigue . This also cause problem treatment psoriasis psoriatic arthritis . Recently different serologic marker find assessment psoriasis psoriatic arthritis . Recent genetic study show different genetic susceptibility gene . We test serologic response three new biologic drug use treatment psoriasis psoriatic arthritis . Paired blood sample patient 12 week treatment use . IL6 decrease alefacept etanercept increase efalizumab treatment without statistical significance ( Paired test : 0.3336、0.2773、0.5904 ) 。IL-8 decreased etanercept increase efalizumab alefacept without statistical significance ( Paired test : 0.4031、0.6749、0.2998 ) 。IL10 decrease efalizumab etanercept , increase significantly alefacept treatment ( Paired test : 0.7254、0.5123、0.0350 ) 。None treatment significant effect TNF-alpha . HC10 decrease alefacept efalizumab , increase etanercept treatmentwithout statistical significance ( Paired test : 0.6589、0.1576、0.1988 ) .</brief_summary>
	<brief_title>Differential Clinical Serologic Response Psoriasis Psoriatic Arthritis Drug Treatment</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Arthritis , Psoriatic</mesh_term>
	<criteria>Clinical diagnosis psoriasis</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2004</verification_date>
	<keyword>psoriatic arthritis</keyword>
</DOC>